Functional Polymorphisms in Cancer Stem Cell Marker Gene CD133 Predict Local Recurrence and Distant

来源 :第十七届全国临床肿瘤学大会暨2014年CSCO学术年会 | 被引量 : 0次 | 上传用户：qweasdzxc34

【摘要】

：

【作者】

：

Qiming Wang Peng Li Hongliang Liu Huihua Xiong Ji Qian Daniel Gomez Zhensheng Liu Li-E Wang Zhongxing Liao Qingyi Wei

【机构】

：

450008 Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University,Henan Can

【出处】

：

第十七届全国临床肿瘤学大会暨2014年CSCO学术年会

【发表日期】

：

2014年11期

下载到本地 , 更方便阅读

下载此文赞助VIP

声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架

论文部分内容阅读

Objective: Cancer stem cells (CSCs) are believed to cause local recurrence, distant metastasis, radiotherapy and chemotherapy resistance.We hypothesized that genetic variation in CD133 (the official name is PROM1), one of the most important marker genes of CSCs, may affect clinical outcomes among non-small cell lung cancer (NSCLC) patients treated with definitive radiotherapy.

其他文献

Safety and efficacy of the Asian subgroup of patients (pts) with EGFR-TKI-resistant advanced non-sma

Objective: AZD9291 is an oral, potent, irreversible EGFR-TKI, selective for sensitizing (EGFRm+) and T790M resistance mutations, currently under investigation in an ongoing Phase Ⅰ study of pts with E

会议

Dacomitinib versus Erlotinib in 2nd-/3rd-line NSCLC (ARCHER 1009 Global Phase Ⅲ trial):Outcomes in C

Objective: Dacomitinib (D) is an irreversible pan-HER kinase inhibitor.The ARCHER 1009 global phase Ⅲ study compared D and erlotinib (E) as treatment for locally advanced/metastatic non-small cell lun

会议

Tumorigenic potential of circulating tumor cells in pulmonary venous blood from Non-Small Cell Lung

Objective: To explore the clinical value and biological characteristics of circulating tumor cells (CTCs) in pulmonary vein (CTCs-pv) from patients with surgically resected non-small cell lung cancer

会议

Safety and clinical activity of pembrolizumab (pembro, MK-3475) in previously-treated patients (pts)

Objective:This Phase Ⅰ study evaluated the safety, tolerability, and clinical activity ofpembro, a selective anti-PD-1 antibody that blocks the interaction between programmed death-1 (PD-1) on T-cells

会议

Prophylactic cranial irradiation improved the overall survival of patients with surgically resected

Objective: We conducted a retrospective study to evaluate the role of prophylactic cranial irradiation (PCI) on patients with surgically resected small cell lung cancer(SCLC).Method: The records of co

会议

Pemetrexed continuation maintenance: An effective tolerable strategy for treating nonsquamous non-sm

Objective: A recent phase 3 study (PARAMOUNT) demonstrated that continuation maintenance therapy of pemetrexed is a new treatment paradigm for advanced nonsquamous NSCLC.The majority of patients enrol

会议

Testicular orphan receptor 4 (TR4) is a marker for metastasis and poor prognosis in NSCLC that drive

Objeetive: NSCLC are particularly aggressive tumors, with high invasive properties and metastatic potential.About 40％ stage Ⅰ and 60％ stage Ⅱ NSCLC patients are dying of distant metastases within 5 ye

会议

The Feasibility of EML4-ALK fusion gene, EGFR and K-ras mutations Detections by Malignant Pleural ef

Objective:To identify the feasibility of pleural effusion detection of epidermal growth factor receptor (EGFR) mutations, echinoderm microtubule-associated protein like 4 (EML4)-anaplastic lymphoma ki

会议

Nivolumab联合厄洛替尼治疗表皮生长因子受体突变(EGFR MT)的晚期NSCLC患者的安全性和缓解率

背景:厄洛替尼已获FDA批准用于表皮生长因子受体突变(EGFR MT)的非小细胞肺癌(NSCLC)一线治疗,中位无进展生存期(PFS)为10.4个月.Nivolumab是全人源化IgG4程序性死亡1(PD-1)免疫检查点抑制剂抗体,作为单药治疗晚期NSCLC患者显示了出令人鼓舞的安全性与生存获益.临床前数据支持EGFR路径活化PD-L1表达与免疫逃避在EGFR驱动的肺肿瘤中的作用.本摘要将报告评估

会议

Safety and clinical activity of pembrolizumab (pembro, MK-3475) as initial therapy in patients with

Objective:Programmed death-1 (PD-1) receptor-ligand interaction inhibits T cell activation against tumor cells.Pembro is a potent and highly selective humanized monoclonal antibody against PD-1 design

会议

Functional Polymorphisms in Cancer Stem Cell Marker Gene CD133 Predict Local Recurrence and Distant

其他学术论文